[go: up one dir, main page]

WO2002066022A1 - Therapie de l'hepatite aux retinoides - Google Patents

Therapie de l'hepatite aux retinoides Download PDF

Info

Publication number
WO2002066022A1
WO2002066022A1 PCT/US2002/002996 US0202996W WO02066022A1 WO 2002066022 A1 WO2002066022 A1 WO 2002066022A1 US 0202996 W US0202996 W US 0202996W WO 02066022 A1 WO02066022 A1 WO 02066022A1
Authority
WO
WIPO (PCT)
Prior art keywords
hepatitis
therapeutically effective
retinoic acid
effective amount
trans retinoic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2002/002996
Other languages
English (en)
Inventor
Anthony H. Williams
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aronex Pharmaceuticals Inc
Original Assignee
Aronex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aronex Pharmaceuticals Inc filed Critical Aronex Pharmaceuticals Inc
Priority to EP02707670A priority Critical patent/EP1363611A4/fr
Priority to CA002437168A priority patent/CA2437168A1/fr
Priority to JP2002565582A priority patent/JP2004522770A/ja
Priority to US10/467,096 priority patent/US20040127566A1/en
Publication of WO2002066022A1 publication Critical patent/WO2002066022A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • This invention is drawn to a method of treating hepatitis comprising
  • the amount of retinoid such as all- trans retinoic acid.
  • the retinoid such as all- trans retinoic acid.
  • hepatitis form of hepatitis is viral hepatitis caused by infection with A, B, C, D, E, and G
  • Hepatitis is an inflammatory liver disease. It is associated with loss of
  • liver may become enlarged and jaundice may be present. Both chronic and acute
  • hepatitis is known.
  • the acute form subsides, generally after about
  • liver disease such as cirrhosis or hepatocellular carcinoma.
  • Type A was previously termed infectious
  • Type B was previously termed serum hepatitis
  • Type C was non-
  • Type D was delta hepatitis.
  • viruses have been known to exhibit hepatitis as a secondary effect. These viruses include Cytomegalovirus, Epstein-Barr virus, as well as Yellow Fever.
  • Hepatitis is also a secondary effect of certain parasites and bacteria infections.
  • Non-viral hepatitis is also associated with autoimmune diseases, Wilson's
  • hemochromatosis and those diseases of toxic origin such as drug,
  • Hepatitis B and C were not drawn.
  • Hepatitis C was not drawn.
  • non-A non-B hepatitis
  • RNA virus of the type described as "Flavivirus” is the cause of Hepatitis C. This
  • RNA virus has been described as a 40-50 nanometer linear single-strand RNA
  • lipid envelope (ribonucleic acid) virus with a lipid envelope.
  • the lipid envelope In native state, the lipid envelope is
  • Hepatitis B is caused by a double
  • stranded DNA virus of the type known as Hepadnavirus . It is a 42 nm particle
  • enterovirus is classified as a genus of the
  • Picornaviridae This genus is generally divided into five major groups.
  • Enteroviruses are characterized by a high degree of genetic diversity at the VP1
  • This invention comprises a method of treating hepatitis comprising
  • a ⁇ - trans retinoic acid (inter alia, liposomal all- trans retinoic acid) of at least about 10mg at least about every other day.
  • retinoic acid are variously at least about 10 mg/m 2 , at least about 15 mg/m 2 , at
  • This method is particularly useful in hepatitis
  • viral hepatitis including hepatitis A, B, C, D, E, or G.
  • This invention also comprises a method of treating hepatitis comprising
  • this includes retinoid in liposomal
  • This invention yet further comprises a method of treating enteroviral
  • this includes retinoid in liposomal form, and further in
  • therapeutically effective amount optionally at least about every other day.
  • group consisting of (i) poliovirus, (ii) group A coxsackievirus, (iii) group B
  • Echovirus 3 4, 6, 7, 9 or 1 1
  • chronic viral disease in a subject comprising administering to said subject a
  • retinoid is at least about 50mg at least about every other day.
  • ATRA refers to a ⁇ -trans retinoic acid, a retinoid. Retinoids in general
  • retinoids include trans-retinoic acid and all- trat?s-retinol.
  • Other retinoids are retinoic acid
  • retinol retinol, retinyl acetate, retinaldehyde, all-trans-retinoic acid, and 13-cis-retinoic
  • Non-liposomal retinoids often suitable for oral administration, are referred to
  • Liposomal ATRA or retinoid shall be broadly understood to encompass
  • lipids are generally spherical structures comprising lipids, fatty acids, lipid bilayer type
  • liposomes are completely closed lipid bilayer membranes containing an entrapped
  • Liposomes may be unilamellar vesicles (possessing a single
  • bilayer membrane or multilamellar vesicles (onion-like structures characterized
  • the bilayer is composed of two lipid monolayers having a hydrophobic
  • bilayer is such that the hydrophobic (nonpolar) "tails" of the lipid monolayers
  • Liposomes are vesicles composed of one or more concentric phospholipid
  • liposome and liposomal.
  • liposome By way of example of such nonliposomal lipid
  • L-ATRA liposomal-ATRA
  • retinoids as
  • liposomal- ATRA or "-retinoid” shall extend to
  • Hepatitis shall be broadly construed in reference to inflammatory liver
  • viral hepatitis are also contemplated within this invention.
  • Therapeutically effective amount as to a drug dosage shall mean that
  • a therapeutically effective amount shall include
  • effective amount is about 50 to about 150 mg administered at least about every
  • a therapeutically effective amount shall mean about
  • ATRA is about 50 to about 150 mg administered at least about every other day.
  • anti-cancer activities retinoids, including ATRA act to reduce the viral load in
  • hepatitis patients with particular reference to hepatitis B and C.
  • hepatitis B and C hepatitis B and C.
  • liposomal retinoid such as L-ATRA is effective.
  • C hepatic enzymes (SPGT and SGOT), bilirubin, and alkaline phosphatase).
  • a 34 year old female is diagnosed by serological tests as positive for
  • a 54 year old male is diagnosed by serological tests as positive for
  • hepatitis A hepatic enzymes
  • APL started to receive L-ATRA (ATRAGEN ® ) QOD at 90 mg/m 2 .
  • ATRAGEN ® L-ATRA
  • liver function test liver function test
  • HCR hematologic complete remission
  • compositions of this invention possess valuable pharmacological properties
  • enteroviruses and hepatitis associated viruses in human and veterinary medicine.
  • compositions are particularly useful in treating hepatitis A, B, C, D, E,
  • compositions can be used in ]n vitro methodologies,
  • the present invention can be employed in admixture with carriers, excipients and
  • compositions of this invention are generally administered to animals,
  • mammals including but not limited to mammals such as livestock, household pets,
  • injectable particularly suitable are injectable.
  • sterile for parenteral application, particularly suitable are injectable.
  • solutions preferably oily or aqueous solutions, as well as suspensions,
  • emulsions or implants, including suppositories.
  • Ampules are convenient unit
  • liquids drops, suppositories, or capsules.
  • a syrup, elixir, or the like can be used
  • compositions of this invention can be any suitable pharmacologically active compositions of this invention.
  • carrier substances suitable for parenteral e.g., enteral (e.g., oral or inhalation) or
  • Suitable pharmaceutically acceptable carriers include but are not limited to
  • compositions can be any suitable pharmaceutical preparations.
  • the pharmaceutical preparations can be any suitable pharmaceutical preparations.
  • auxiliary agents e.g. They can also be
  • antiviral drugs such as alpha interferon, ribavirin, amantadine,
  • ganciclovir dideoxycytosine, dideoxyinosine
  • rimantadine stavudine, famciclovir, and trifluridine.
  • dosage forms include
  • injectable, sterile are particularly suitable are injectable, sterile
  • solutions preferably suspensions.
  • Ampules are convenient unit dosages.
  • Sustained or directed release compositions can be formulated, e.g.,
  • degradable coatings e.g., by microencapsulation, multiple coatings, etc. It is
  • compositions of this invention are dispensed in unit dosage
  • liposomal ATRA of from 1 5 to 300 or more mg/m 2 and
  • compositions in a specific case will vary according to the specific compositions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne une méthode de traitement de l'hépatite, consistant à administrer à un sujet une quantité thérapeutiquement efficace de rétinoïdes, tels que de l'acide tout-trans rétinoïque. Dans des modes de réalisation particuliers, la forme d'hépatite est l'hépatite A, B, C, D, E et G et le traitement s'effectue au moyen d'acide tout-trans rétinoïque liposomal.
PCT/US2002/002996 2001-02-02 2002-01-31 Therapie de l'hepatite aux retinoides Ceased WO2002066022A1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP02707670A EP1363611A4 (fr) 2001-02-02 2002-01-31 Therapie de l'hepatite aux retinoides
CA002437168A CA2437168A1 (fr) 2001-02-02 2002-01-31 Therapie de l'hepatite aux retinoides
JP2002565582A JP2004522770A (ja) 2001-02-02 2002-01-31 レチノイド肝炎治療
US10/467,096 US20040127566A1 (en) 2002-01-31 2002-01-31 Retinoid hepatitis therapy

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26597701P 2001-02-02 2001-02-02
US60/265,977 2001-02-02

Publications (1)

Publication Number Publication Date
WO2002066022A1 true WO2002066022A1 (fr) 2002-08-29

Family

ID=23012660

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/002996 Ceased WO2002066022A1 (fr) 2001-02-02 2002-01-31 Therapie de l'hepatite aux retinoides

Country Status (4)

Country Link
EP (1) EP1363611A4 (fr)
JP (1) JP2004522770A (fr)
CA (1) CA2437168A1 (fr)
WO (1) WO2002066022A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10305138A1 (de) * 2003-02-07 2004-08-26 Axxima Pharmaceuticals Ag Gegen Hepatitis C-Virusinfektionen nützliche Verbindungen und Substanzen
WO2004050101A3 (fr) * 2002-11-29 2004-09-10 Axxima Pharmaceuticals Ag Formulations utiles pour lutter contre les infections par le virus de l'hepatite c
WO2005120479A1 (fr) * 2004-06-09 2005-12-22 Gpc Biotech Ag Utilisation de selenium ou d'un sel de selenium et d'un acide retinoique ou d'un retinoide pour traiter une hepatite c virale
WO2018054891A1 (fr) * 2016-09-20 2018-03-29 Ruprecht-Karls-Universität Composés et leurs combinaisons de prévention et/ou de traitement d'infections par le hbv et/ou le hdv

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166319A (en) * 1989-10-10 1992-11-24 Brunswick Corporation Interfacial condensation of bioactive compounds and the site-specific compounds and conjugates thereof
US5811119A (en) * 1987-05-19 1998-09-22 Board Of Regents, The University Of Texas Formulation and use of carotenoids in treatment of cancer
US6093741A (en) * 1996-02-15 2000-07-25 Virocell Inc. Agents with leukotriene B4-like activity as antiherpes viral agents

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5824313A (en) * 1989-09-25 1998-10-20 University Of Utah Research Foundation Vaccine compositions and method for induction of mucosal immune response via systemic vaccination
US6028088A (en) * 1998-10-30 2000-02-22 The University Of Mississippi Flavonoid derivatives
GB0020351D0 (en) * 2000-08-17 2000-10-04 Catalyst Biomedica Ltd Treatment of hyperproliferative diseases

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811119A (en) * 1987-05-19 1998-09-22 Board Of Regents, The University Of Texas Formulation and use of carotenoids in treatment of cancer
US5166319A (en) * 1989-10-10 1992-11-24 Brunswick Corporation Interfacial condensation of bioactive compounds and the site-specific compounds and conjugates thereof
US6093741A (en) * 1996-02-15 2000-07-25 Virocell Inc. Agents with leukotriene B4-like activity as antiherpes viral agents

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1363611A4 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004050101A3 (fr) * 2002-11-29 2004-09-10 Axxima Pharmaceuticals Ag Formulations utiles pour lutter contre les infections par le virus de l'hepatite c
JP2006514094A (ja) * 2002-11-29 2006-04-27 ゲーペーツェー バイオテック アクチェンゲゼルシャフト Ｃ型肝炎ウイルス感染に対して有用な製剤
DE10305138A1 (de) * 2003-02-07 2004-08-26 Axxima Pharmaceuticals Ag Gegen Hepatitis C-Virusinfektionen nützliche Verbindungen und Substanzen
WO2005120479A1 (fr) * 2004-06-09 2005-12-22 Gpc Biotech Ag Utilisation de selenium ou d'un sel de selenium et d'un acide retinoique ou d'un retinoide pour traiter une hepatite c virale
WO2018054891A1 (fr) * 2016-09-20 2018-03-29 Ruprecht-Karls-Universität Composés et leurs combinaisons de prévention et/ou de traitement d'infections par le hbv et/ou le hdv

Also Published As

Publication number Publication date
JP2004522770A (ja) 2004-07-29
CA2437168A1 (fr) 2002-08-29
EP1363611A4 (fr) 2004-08-11
EP1363611A1 (fr) 2003-11-26

Similar Documents

Publication Publication Date Title
RU2659729C2 (ru) Кохлеаты, полученные с использованием фосфатидилсерина сои
AU2023204000A1 (en) Mast cell stabilizers for treatment of hypercytokinemia and viral infection
WO2010128889A1 (fr) Composition pharmaceutique comprenant de l'arbidol sous forme de nanoparticules de phospholipides
JPH07509730A (ja) ウイルス感染の治療におけるジデオキシヌクレオシドアナローグの使用
TWI302459B (fr)
JPH11514990A (ja) ２−メルカプトエタノールアミン（２−ｍｅａ）と類縁アミノチオール化合物および３，５−ジイソプロピルサリチル酸銅（▲ｉｉ▼）と類縁化合物の、各種疾患を予防および治療するための使用
US20230263748A1 (en) Application of benflumetol and derivatives thereof in treatment of coronavirus infection
WO2006092741A2 (fr) Traitement des troubles inflammatoires avec du praziquantel
WO2002066022A1 (fr) Therapie de l'hepatite aux retinoides
CN1533776A (zh) N-乙酰氨基葡萄糖在制备用于治疗病毒或细菌感染所致的局部损伤和全身症状的药物中的应用
US20040127566A1 (en) Retinoid hepatitis therapy
EP1868572A2 (fr) Administration de glutathion (reduit) par intraveineuse ou encapsule dans des liposomes pour le traitement des effets du tnf-$g(a) et des symptomes viraux pseudogrippaux
CN101597312A (zh) 维甲酰阿糖胞苷缀合物及其药质体、其制备方法和应用
JP2002535371A (ja) リバビリンによる免疫応答の調節
WO1989001764A1 (fr) Palliatif destine au syndrome d'immunodeficience acquise/complexe relatif au syndrome d'immunodeficience acquise
CN107281199A (zh) N‑乙酰‑d‑氨基葡萄糖及其药物可接受盐在制备治疗病毒性肝炎药物中的应用及药物
CN101019872B (zh) 抗病毒纳米脂质体药物及其制备方法
RU2104023C1 (ru) Лекарственное средство для лечения ретровирусных инфекций
DE3780157T2 (de) Verwendung von 4-butyl-1,2-diphenyl-pyrazolidin-3,5-dion als antivirales arzneimittel gegen aids.
US20100016244A1 (en) D-glucopyranose 1-[3,5-bis (1,1-dimethylethy)-4-hydroxybenzoate] and its derivatives, preparation and use thereof
Kocięcka et al. The effect of Thymus Factor X (TFX Polfa) on the clinical course of human trichinellosis
US20230129386A1 (en) Treatment of covid-19 with reverse micelle system comprising unmodified oligonucleotides
CN102793740B (zh) 一种对化学性肝损伤有辅助保护功能的营养颗粒
CN102389564A (zh) 用于治疗骨髓增生异常综合征的组合物和方法及用途
CA2277053A1 (fr) Traitement d'infections a rhinovirus

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2437168

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002565582

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2002707670

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002707670

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10467096

Country of ref document: US

WWW Wipo information: withdrawn in national office

Ref document number: 2002707670

Country of ref document: EP